Amyloid deposits are often found in the bone marrow in patients with AL amyloidosis; we sought to determine whether this affects stem cell collection or engraftment following high dose melphalan and autologous stem cell transplantation (HDM/SCT). Data on 361 patients with AL amyloidosis who had Congo red staining of the pre-treatment bone marrow biopsy and underwent HDM/SCT from July 1994 to December 2011 were reviewed. Data were analyzed for stem cell yield, number of days of stem cell collection, neutrophil and platelet engraftment post SCT. Sixty-five % of patients (n=233) had bone marrow amyloid deposits. There were no significant differences in median number of stem cells collected, days to neutrophil or platelet engraftment between patients with and without bone marrow amyloid deposits. Thus, while amyloid involvement of the bone marrow is common, it does not negatively impact stem cell mobilization or neutrophil and platelet engraftment after HDM/SCT.